Compare · AKYA vs AVTR
AKYA vs AVTR
Side-by-side comparison of Akoya BioSciences Inc. (AKYA) and Avantor Inc. (AVTR): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AKYA and AVTR operate in Biotechnology: Laboratory Analytical Instruments (Health Care), so they compete in similar markets.
- AVTR carries a market cap of $10.38B.
- AVTR has hit the wire 8 times in the past 4 weeks while AKYA has been quiet.
- AVTR has more recent analyst coverage (25 ratings vs 13 for AKYA).
- Company
- Akoya BioSciences Inc.
- Avantor Inc.
- Price
- -
- -
- Market cap
- -
- $10.38B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2021
- 2019
- News (4w)
- 0
- 8
- Recent ratings
- 13
- 25
Akoya BioSciences Inc.
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research. The company offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. It provides two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational, and clinical research. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.
Avantor Inc.
Avantor, Inc. provides products and services to customers in biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, and clinical trial kits. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Avantor, Inc. was founded in 1904 and is headquartered in Radnor, Pennsylvania.
Latest AKYA
- SEC Form 15-12G filed by Akoya BioSciences Inc.
- SEC Form EFFECT filed by Akoya BioSciences Inc.
- Director Mendel Scott disposed of 28,500 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Business Officer Ramachandran Niro Ph.D acquired 62,566 shares, covered exercise/tax liability with 42,148 shares and disposed of 282,555 shares, closing all direct ownership in the company (SEC Form 4)
- President and CEO Mckelligon Brian disposed of 947,688 shares, acquired 724,428 shares and covered exercise/tax liability with 196,866 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Legal Officer Kamocsay Jennifer disposed of 179,272 shares, closing all direct ownership in the company (SEC Form 4)
- CFO Ek John Frederick disposed of 268,202 shares, closing all direct ownership in the company (SEC Form 4)
- Chief Clinical Officer Bamford Pascal disposed of 205,738 shares, closing all direct ownership in the company (SEC Form 4)
- Director Winkler Matthew disposed of 984,513 shares, closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Shepler Robert G
Latest AVTR
- EVP, Chief Operating Officer Blenn Mary covered exercise/tax liability with 2,900 shares, decreasing direct ownership by 1% to 250,484 units (SEC Form 4) to satisfy withholding obligation
- EVP, Chief Legal & Compliance Sokenu Claudius was granted 62,305 shares, increasing direct ownership by 25% to 313,533 units (SEC Form 4)
- EVP, Chief HR Officer Hankamer Brittany was granted 46,728 shares, increasing direct ownership by 19% to 295,592 units (SEC Form 4)
- Avantor Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- SEC Form 10-Q filed by Avantor Inc.
- SEC Form 8-K filed by Avantor Inc.
- Avantor® Reports Third Quarter 2026 Results
- Avantor appoints new Chief Information Officer
- Healthcare Stocks Rushing Higher, with Oncology Push, Breakout Test, and Lilly’s Next Growth Chapter
- Avantor® to Report Third Quarter 2026 Earnings on Wednesday, October 28, 2026